Organization | Immunocore Ltd

Immunocore Ltd Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3

Founded: Abingdon United Kingdom (2008)

Organization Overview

First Clinical Trial

2010

NCT01211262

First Marketed Drug

2022

tebentafusp (Kimmtrak)

First NDA Approval

2022

tebentafusp (Kimmtrak)

Last Known Activity

2023

Timeline

NOW

Now

Alternative names

Immunocore Limited | Immunocore Ltd | IMMUNOCORE LTD

Active Ingredients

Marketed Drugs (1)

tebentafusp (Kimmtrak) (2022 NDA)

Drugs in Phase 3 Trials (5)

imc-f106c (2 trials)

nivolumab (opdivo) (1 trial)

pembrolizumab (keytruda) (2 trials)

relatlimab (Opdualag) (1 trial)

tebentafusp (Kimmtrak) (9 trials)

Drugs in Phase 2 Trials (7)

atezolizumab (Tecentriq) (1 trial)

dacarbazine (dtic-dome) (1 trial)

durvalumab (imfinzi) (1 trial)

imc-c103c (1 trial)

imcnyeso (1 trial)

ipilimumab (yervoy) (1 trial)

tremelimumab (Imjudo) (1 trial)

Drugs in Phase 1 Trials (1)

imc-i109v-101 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Melanoma (Phase 2)

Uveal Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 13